TTC6

Across TCGA pan-cancer cohorts, TTC6 RNA differs between tumor and matched normal tissue in 13 of 18 cancer types tested, making tumor–normal expression one of TTC6’s most consistent transcriptional readouts.

The strongest signal is observed in breast invasive carcinoma (BRCA), where TTC6 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types TTC6 is over-expressed in tumor, although a few such as LUSC and HNSC show the opposite, repressed pattern.

BRCA, LUSC, and HNSC are the cancer types where TTC6 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in TTC6 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
BRCA	All	All	+0.430	.017	4	view →
LUSC	Male	II,III,IV	−0.410	.001	4	view →
HNSC	Female	II,III,IV	−0.255	.007	4	view →
COAD	Female	III,IV	−0.319	.020	3	view →
LIHC	All	All	+0.202	.003	3	view →
PRAD	All	All	+0.997	<.001	2	view →
UCEC	All	All	+0.404	.033	2	view →
READ	All	II,III,IV	−0.202	.020	2	view →
KIRP	All	All	+0.107	.041	2	view →
ESCA	All	All	−0.757	.039	1	view →
STAD	All	All	+0.269	.033	1	view →
STAD	Male	IV	−0.210	.002	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 13 lineages.

TTC6–BRCA

Open the BRCA breakdown →